Objectives: The aim of this work was to study the epidemiology of urogenital trichomoniasis in the setting of systematic screening of STIs, using a multiplex molecular assay. Besides, the specificity for T. vaginalis detection of the syndromic panel was assessed comparatively to an in-house PCR.
Methods: 41,507 samples sent for STI screening between 2020 and 2024 were analysed using the Allplex® STI Essential molecular panel targeting T. vaginalis, C. trachomatis, N. gonorrhoeae, M. genitalium, M. hominis, Ureaplasma parvum, and U. urealyticum. Remaining samples positive for T. vaginalis were stored for confirmation using a simplex in-house qPCR assay targeting the beta-tubulin gene.
Results: 337 (0.8%) samples (282 patients; 0.93%) were positive for T. vaginalis. The highest rate of positivity was observed in patients aged between 20 and 24 (1.6%), whereas the number of cases over 45 years was anecdotal (0.4%). Prevalence was ten times lower in men than in women. Twenty-four percent were co-infected with at least one pathogen, i.e., C. trachomatis (n=17%) and/or M. genitalium (9.2%) and/or N. gonorrhoeae (3.6%). More than half patients positive for T. vaginalis were asymptomatic, of whom 88% were treated. Symptomatic patients presented mostly with abnormal leucorrhea, pruritus and/or dysuria. Amplification of 160 samples by simplex PCRs showed an excellent concordance rate of 95% (n= 152/160) with the multiplex PCR.
Conclusions: Allplex® STI Essential multiplex PCR assay improves the detection of T. vaginalis with an excellent specificity and therefore represents an interesting tool to evaluate the prevalence of this neglected infection.
Keywords: Sexually transmitted infections; Syndromic PCR; Trichomonas vaginalis; Trichomoniasis.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.